Vijaypd Ceutical Ltd Q4FY25 IPO – 98% Revenue Growth, 191% PAT Jump, From Distributor to API Manufacturer?

Search for stocks /

IPO

Vijaypd Ceutical Ltd Q4FY25 IPO – 98% Revenue Growth, 191% PAT Jump, From Distributor to API Manufacturer?

|September 28, 2025

1. At a Glance

Vijaypd Ceutical, a pharma distributor born in 1971, is going SME with a ₹19.25 Cr fixed-price IPO at ₹35/share. The lot size is a heavyweight 4,000 shares. Retail investors must cough up ₹2.8 lakh (min 2 lots)—so forget your chai-samosa SIP crowd; only serious bidders allowed. HNIs? ₹4.2 lakh minimum. Listing is set for NSE SME on Oct 7, 2025.

What’s juicy? FY25 revenue doubled to ₹107.6 Cr from ₹54.3 Cr in FY24, while PAT nearly tripled to ₹4.8 Cr. Debt has slimmed down from ₹30 Cr to ₹21.7 Cr, but leverage still lurks. Promoters are diluting from 78% to 56%, a chunky 22% drop. Why? To fund their API/intermediates plant in MIDC Ahmednagar (₹10.8 Cr capex), repay ₹5.1 Cr loans, and of course, “general corporate purposes” (aka the IPO’s samosa budget).

So the pitch is clear: from distributor of 19,000 SKUs to manufacturer of APIs. Big leap, but can a ₹20 Cr raise turn a 50-year-old distributor into a manufacturing contender?

2. Introduction

Let’s be honest—“Vijaypd Ceutical” sounds like the pharma cousin of your neighborhood Kirana store: “aapko tablet chahiye ya shampoo?” And that’s not far from reality. They’re stockists, agents, packers, distributors—serving 2,109 pharmacies, clinics, and nursing homes across 20 locations.

But here’s the twist: they want to climb the pharma value chain. Instead of just supplying other people’s drugs, they now want to make their own APIs and intermediates. IPO money = land, plant, machinery at MIDC Shrirampur.

This isn’t a vanity project. Margins in distribution are razor-thin (EBITDA margin FY25 = 8%), but in APIs, if executed well, margins can skyrocket. The risk? Manufacturing is a different beast—compliance, R&D, process chemistry, scale economics. Going from middleman to manufacturer is like a delivery boy deciding to run a cloud kitchen—doable, but not guaranteed.

3. Business Model – WTF Do They Even Do?

Currently, Vijaypd Ceutical is a pharma and FMCG distributor with:

Products: medicines, vitamins, enzymes, diagnostics kits, baby care, ayurvedic, cosmetics, food products.
Network: over 2,100 pharmacies & hospitals, 170+ manufacturers tied up, 19,000+ SKUs.
Certifications: FDA, FSSAI, BMC—legit paperwork, not WhatsApp approvals.

Revenue = distributor commissions and margins on stock. Nothing fancy.

But post-IPO plan = API/intermediates manufacturing unit at MIDC Ahmednagar. This is a strategic pivot—if successful, they move from a commodity distributor to value-added pharma player.

So WTF do they do? Today = distribution, tomorrow = APIs. Ambition level = high. Execution risk = higher.

4. Financials Overview

Metric	FY25	FY24	FY23	YoY %
Revenue	₹107.6 Cr	₹54.3 Cr	₹50.6 Cr	+98%
EBITDA	₹8.6 Cr	₹4.9 Cr	₹1.3 Cr	+76%
PAT	₹4.8 Cr	₹1.65 Cr	₹0.18 Cr	+191%
EPS (₹)	2.45	0.85	0.10	+188%

Commentary: Doubling revenue and tripling PAT looks spectacular. But PAT margin = 4.5%, EBITDA margin = 8%. These are thin, distributor-style numbers. API business is needed to fatten these margins. Post IPO EPS dilution will drag, but growth gives some comfort.